Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy

7 May 2024

Abstract excerpt

The introduction of chimeric antigen receptor (CAR) T-cell therapy represents a landmark advancement in treating resistant forms of cancer such as leukemia, lymphoma, and myeloma. However, concerns about long-term safety have emerged following an FDA investigation into reports of second primary malignancies (SPM) after CAR-T cell treatment. This review offers a thorough examination of how genetically modified T...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosimilars and Bioanalytical Methods
Share to CAR-T cell therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38713831
DOI: 10.1158/2643-3230.bcd-23-0272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell MalignancyPMID 38713831Read ↗

T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalitiesSemantic proximity Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cellsSemantic proximity Read ↗

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapySemantic proximity Read ↗

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic ReprogrammingSemantic proximity Read ↗

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphomaSemantic proximity Read ↗

T-Cell Cancer after CAR T-Cell TherapySemantic proximity Read ↗

Emerging Cellular Therapies for CancerSemantic proximity Read ↗

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.